{"commentary":{"count":42,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":34,"youtube":7,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04334941\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04334941","nct_id":"NCT04334941","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04334941. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive atezolizumab IV over 60 (+/- 15) minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.","label":"Arm I (atezolizumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive atezolizumab IV over 60 (+/- 15) minutes on day 1 and talazoparib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.","label":"Arm II (atezolizumab, talazoparib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-01-21","type":"ESTIMATED"},"conditions":["Extensive Stage Lung Small Cell Carcinoma"],"enrollment":{"count":103,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Biopsy Procedure","type":"PROCEDURE"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Talazoparib","type":"DRUG"}],"last_update":"2026-06-05","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"From the date of maintenance randomization to the date of first document of progression or symptomatic deterioration, or death due to any cause, assessed up to 18 months"}],"references":[],"start_date":{"date":"2020-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","url":"https://clinicaltrials.gov/study/NCT04334941"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04334941"}